7-fluorospiro[chromene-2,4'-piperidin]-4(3H)-one hydrochloride hydrate | 936648-41-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 7-fluorospiro[chromene-2,4'-piperidin]-4(3H)-one hydrochloride hydrate
• 英文别名: 7-Fluorospiro[chroman-2,4'-piperidin]-4-one hydrochloride；7-fluorospiro[3H-chromene-2,4'-piperidine]-4-one;hydrochloride
• CAS: 936648-41-8
• 化学式: C₁₃H₁₄FNO₂*ClH
• 分子量: 271.719
• InChiKey: UFMIWJUCWGFHTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.33
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  38.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-fluorospiro[chromene-2,4'-piperidin]-4(3H)-one hydrochloride hydrate 、 6-chloro-N-(2-hydroxy-2-phenylethyl)pyridazine-3-carboxamide 以 正丁醇 为溶剂， 生成
  参考文献：
  名称：

  Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4′-piperidine]

  摘要：

  Cyclization of the benzoylpiperidine in lead compound 2 generated a series of novel and highly potent spiropiperidine-based stearoyl-CoA desaturase (SCD)-1 inhibitors. Among them, 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine] (19) demonstrated the most powerful inhibitory activity against SCD-1, not only in vitro but also in vivo (C57BL/6 J mice). With regard to the pharmacological evaluation, 19 showed powerful reduction of the desaturation index in the plasma of C57BL/6 J mice on a non-fat diet after a 7-day oral administration (q.d.) without causing notable abnormalities in the eyes or skin up to the highest dose (3 mg/kg) in our preliminary analysis. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.043
• 作为产物：
  描述：

  tert-butyl 7-fluoro-4-oxospiro[chroman-2,4'-piperidine]-1'-carboxylate 在 盐酸 、 水 作用下， 以 异丙醇 为溶剂， 反应 3.0h， 以99%的产率得到7-fluorospiro[chromene-2,4'-piperidin]-4(3H)-one hydrochloride hydrate
  参考文献：
  名称：

  WO2008/65508

  摘要：

  公开号：

文献信息

• SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE
  申请人：Dales Natalie

  公开号：US20120010135A1

  公开（公告）日：2012-01-12

  The present invention provides spiro derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了螺环衍生物，可以调节硬脂酰辅酶A脱饱和酶的活性。还包括使用这些衍生物调节硬脂酰辅酶A脱饱和酶的方法以及包含这些衍生物的制药组合物。
• WO2008/65508
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE<br/>[FR] DÉRIVÉS SPIRO POUR LA MODULATION DE LA STÉAROYL-COA DÉSATURASE
  申请人：NOVARTIS AG

  公开号：WO2010112520A1

  公开（公告）日：2010-10-07

  The present invention provides spiro derivatives that modulate the activity of stearoyl- CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl- CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
• Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4′-piperidine]
  作者：Yoshikazu Uto、Yohei Kiyotsuka、Yuko Ueno、Yuriko Miyazawa、Hitoshi Kurata、Tsuneaki Ogata、Tsuneo Deguchi、Makiko Yamada、Nobuaki Watanabe、Masahiro Konishi、Nobuya Kurikawa、Toshiyuki Takagi、Satoko Wakimoto、Keita Kono、Jun Ohsumi

  DOI：10.1016/j.bmcl.2009.11.043

  日期：2010.1

  Cyclization of the benzoylpiperidine in lead compound 2 generated a series of novel and highly potent spiropiperidine-based stearoyl-CoA desaturase (SCD)-1 inhibitors. Among them, 1'-6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine] (19) demonstrated the most powerful inhibitory activity against SCD-1, not only in vitro but also in vivo (C57BL/6 J mice). With regard to the pharmacological evaluation, 19 showed powerful reduction of the desaturation index in the plasma of C57BL/6 J mice on a non-fat diet after a 7-day oral administration (q.d.) without causing notable abnormalities in the eyes or skin up to the highest dose (3 mg/kg) in our preliminary analysis. (C) 2009 Elsevier Ltd. All rights reserved.